Literature DB >> 21655149

O. Harold Warwick: Canada's first medical oncologist.

D H Cowan1.   

Abstract

O. Harold Warwick graduated in medicine from McGill University as a gold medalist and Rhodes Scholar in 1940. After World War II, he started postgraduate training in Montreal, and in 1946, he began studying the newly described drug treatment of cancer in London, England. There he carried out the first study of nitrogen mustard in a group of adult patients with a non-hematologic solid tumour, lung cancer. After a brief period of practice in Montreal, he moved in 1948 to Toronto, where he became executive director of the Canadian Cancer Society and the National Cancer Institute of Canada. Simultaneously, he joined the staff of Toronto General Hospital and its Radiotherapy Institute, where he became the first physician-oncologist to provide medical care and administer anticancer drugs in a Canadian cancer centre. In 1958, the new Princess Margaret Hospital opened in Toronto; Warwick became its first chief physician, responsible for clinical drug trials. Here he carried out his best known clinical study-the use of vinblastine sulphate in patients with Hodgkin lymphoma. From 1961 to 1971, he served as dean and then vice-president Health Sciences at the University of Western Ontario. He returned to the practice of medical oncology from 1972 to 1980 at the London Cancer Clinic, after which he had a long and productive retirement. He died in October 2009. Although the specialty was not named until the latter years of his career, Harold Warwick satisfied all the criteria for and was undoubtedly Canada's first medical oncologist.

Entities:  

Keywords:  Harold Warwick; history; medical oncology

Year:  2011        PMID: 21655149      PMCID: PMC3108871          DOI: 10.3747/co.v18i3.425

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  13 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

2.  The clinical features of hypercalcemia associated with malignant disease.

Authors:  O H WARWICK; E R YENDT; J S OLIN
Journal:  Can Med Assoc J       Date:  1961-09-23       Impact factor: 8.262

3.  Clinical experience with vinblastine sulfate.

Authors:  O H WARWICK; R E ALISON; J M DARTE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

4.  Some biological effects of Vincaleukoblastine, an alkaloid in Vinca rosea Linn in patients with malignant disease.

Authors:  O H WARWICK; J M DARTE; T C BROWN; C T BEER; J H CUTTS; R L NOBLE
Journal:  Cancer Res       Date:  1960-08       Impact factor: 12.701

5.  Effect of Vincaleukoblastine on metastatic choriocarcinoma and related trophoblastic tumors in women.

Authors:  R HERTZ; M B LIPSETT; R H MOY
Journal:  Cancer Res       Date:  1960-08       Impact factor: 12.701

6.  Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.

Authors:  L S GOODMAN; M M WINTROBE
Journal:  J Am Med Assoc       Date:  1946-09-21

7.  Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system.

Authors:  L O JACOBSON; C L SPURR
Journal:  J Am Med Assoc       Date:  1946-10-05

8.  Influence of Synthetic Oestrogens on Advanced Malignant Disease.

Authors:  A Haddow; J M Watkinson; E Paterson; P C Koller
Journal:  Br Med J       Date:  1944-09-23

9.  Nitrogen mustards in the treatment of neoplastic disease; official statement.

Authors:  C P RHOADS
Journal:  J Am Med Assoc       Date:  1946-06-22

10.  The effects of chloroethylamines on tumours, with special reference to bronchogenic carcinoma.

Authors:  E BOYLAND; J W CLEGG
Journal:  Br J Cancer       Date:  1948-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.